BeOne Medicines teams with Revolution Medicines on RAS cancer drug development, Asia rights deal

• BeOne Medicines AG entered a multi-part collaboration with Revolution Medicines covering clinical development and regional commercialization for RAS(ON) cancer drugs.
• The partners will test combination regimens pairing select BeOne oncology assets with Revolution’s four clinical-stage RAS(ON) inhibitors.
• BeOne received exclusive rights in select Asian markets to develop or commercialize those four assets, while Revolution retained rights outside the territory.
• BeOne will fund and run a global registrational Phase 3 trial for one of the RAS(ON) inhibitors.
• Revolution is eligible for development and sales milestones, plus tiered royalties on partnered-region net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608100600BIZWIRE_USPR_____20260810_BW801799) on August 10, 2026, and is solely responsible for the information contained therein.